Synaptogenix, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 6.04 million compared to USD 5.57 million a year ago. Basic loss per share from continuing operations was USD 29.5 compared to USD 20.25 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.57 USD | -2.97% | -10.22% | -32.77% |
04-09 | Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd. | CI |
04-03 | Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall | MT |
1st Jan change | Capi. | |
---|---|---|
-32.77% | 4.96M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+46.28% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- SNPX Stock
- News Synaptogenix, Inc.
- Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023